176 related articles for article (PubMed ID: 32231423)
1. Landscape of BRIP1 molecular lesions in gastrointestinal cancers from published genomic studies.
Voutsadakis IA
World J Gastroenterol; 2020 Mar; 26(11):1197-1207. PubMed ID: 32231423
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Mutational Analysis of the BRCA1-Associated DNA Helicase and Tumor-Suppressor FANCJ/BACH1/BRIP1.
Calvo JA; Fritchman B; Hernandez D; Persky NS; Johannessen CM; Piccioni F; Kelch BA; Cantor SB
Mol Cancer Res; 2021 Jun; 19(6):1015-1025. PubMed ID: 33619228
[TBL] [Abstract][Full Text] [Related]
3. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
[TBL] [Abstract][Full Text] [Related]
4. Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.
Guénard F; Labrie Y; Ouellette G; Joly Beauparlant C; Simard J; ; Durocher F
J Hum Genet; 2008; 53(7):579. PubMed ID: 18414782
[TBL] [Abstract][Full Text] [Related]
5. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.
Seal S; Thompson D; Renwick A; Elliott A; Kelly P; Barfoot R; Chagtai T; Jayatilake H; Ahmed M; Spanova K; North B; McGuffog L; Evans DG; Eccles D; ; Easton DF; Stratton MR; Rahman N
Nat Genet; 2006 Nov; 38(11):1239-41. PubMed ID: 17033622
[TBL] [Abstract][Full Text] [Related]
6. A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function.
De Nicolo A; Tancredi M; Lombardi G; Flemma CC; Barbuti S; Di Cristofano C; Sobhian B; Bevilacqua G; Drapkin R; Caligo MA
Clin Cancer Res; 2008 Jul; 14(14):4672-80. PubMed ID: 18628483
[TBL] [Abstract][Full Text] [Related]
7. Rare
Moyer CL; Ivanovich J; Gillespie JL; Doberstein R; Radke MR; Richardson ME; Kaufmann SH; Swisher EM; Goodfellow PJ
Cancer Res; 2020 Feb; 80(4):857-867. PubMed ID: 31822495
[TBL] [Abstract][Full Text] [Related]
8. BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases.
Suszynska M; Ratajska M; Kozlowski P
J Ovarian Res; 2020 May; 13(1):50. PubMed ID: 32359370
[TBL] [Abstract][Full Text] [Related]
9. FancJ (Brip1) loss-of-function allele results in spermatogonial cell depletion during embryogenesis and altered processing of crossover sites during meiotic prophase I in mice.
Sun X; Brieño-Enríquez MA; Cornelius A; Modzelewski AJ; Maley TT; Campbell-Peterson KM; Holloway JK; Cohen PE
Chromosoma; 2016 Jun; 125(2):237-52. PubMed ID: 26490168
[TBL] [Abstract][Full Text] [Related]
10. Helicase-inactivating
Kamal L; Pierce SB; Canavati C; Rayyan AA; Jaraysa T; Lobel O; Lolas S; Norquist BM; Rabie G; Zahdeh F; Levy-Lahad E; King MC; Kanaan MN
Cold Spring Harb Mol Case Stud; 2020 Oct; 6(5):. PubMed ID: 33028645
[TBL] [Abstract][Full Text] [Related]
11. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626
[TBL] [Abstract][Full Text] [Related]
12. Novel role of BRCA1 interacting C-terminal helicase 1 (BRIP1) in breast tumour cell invasion.
Rizeq B; Sif S; Nasrallah GK; Ouhtit A
J Cell Mol Med; 2020 Oct; 24(19):11477-11488. PubMed ID: 32888398
[TBL] [Abstract][Full Text] [Related]
13. Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1.
Cantor SB; Guillemette S
Future Oncol; 2011 Feb; 7(2):253-61. PubMed ID: 21345144
[TBL] [Abstract][Full Text] [Related]
14. Loss of heterozygosity in FANCG, FANCF and BRIP1 from head and neck squamous cell carcinoma of the oral cavity.
Türke C; Horn S; Petto C; Labudde D; Lauer G; Wittenburg G
Int J Oncol; 2017 Jun; 50(6):2207-2220. PubMed ID: 28440438
[TBL] [Abstract][Full Text] [Related]
15. Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy.
Eelen G; Vanden Bempt I; Verlinden L; Drijkoningen M; Smeets A; Neven P; Christiaens MR; Marchal K; Bouillon R; Verstuyf A
Oncogene; 2008 Jul; 27(30):4233-41. PubMed ID: 18345034
[TBL] [Abstract][Full Text] [Related]
16. BRCA1-mediated repression of mutagenic end-joining of DNA double-strand breaks requires complex formation with BACH1.
Dohrn L; Salles D; Siehler SY; Kaufmann J; Wiesmüller L
Biochem J; 2012 Feb; 441(3):919-26. PubMed ID: 22032289
[TBL] [Abstract][Full Text] [Related]
17. Unraveling the molecular effect of a rare missense mutation in BRIP1 associated with inherited breast cancer.
Velázquez C; Esteban-Cardeñosa EM; Lastra E; Abella LE; de la Cruz V; Lobatón CD; Durán M; Infante M
Mol Carcinog; 2019 Jan; 58(1):156-160. PubMed ID: 30230034
[TBL] [Abstract][Full Text] [Related]
18. FANCJ helicase promotes DNA end resection by facilitating CtIP recruitment to DNA double-strand breaks.
Nath S; Nagaraju G
PLoS Genet; 2020 Apr; 16(4):e1008701. PubMed ID: 32251466
[TBL] [Abstract][Full Text] [Related]
19.
Martín-Morales L; Garre P; Lorca V; Cazorla M; Llovet P; Bando I; García-Barberan V; González-Morales ML; Esteban-Jurado C; de la Hoya M; Castellví-Bel S; Caldés T
Cancer Prev Res (Phila); 2021 Feb; 14(2):185-194. PubMed ID: 33115781
[TBL] [Abstract][Full Text] [Related]
20. Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas.
Moes-Sosnowska J; Rzepecka IK; Chodzynska J; Dansonka-Mieszkowska A; Szafron LM; Balabas A; Lotocka R; Sobiczewski P; Kupryjanczyk J
Cancer Biol Ther; 2019; 20(6):843-854. PubMed ID: 30822218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
